RCT | Cemiplimab plus chemotherapy vs. chemotherapy alone in non-small cell lung cancer.
29 Aug, 2022 | 12:08h | UTC
Commentary on Twitter
Results from EMPOWER-Lung 3 demonstrate increased overall survival with #cemiplimab plus platinum-doublet #chemotherapy compared with cemiplimab as first-line treatment in patients with advanced non-small cell #LungCancer, irrespective of #PD-L1 expressionhttps://t.co/ojCDeivKzC
— Nature Medicine (@NatureMedicine) August 25, 2022